AI-driven disruption to drive the Ovarian Reserve Test Market

New York, United States, 2022-May-10 — /EPR Network/ —

The healthcare vertical is expected to accelerate based on IoMT (Internet of Medical Technology). The key players in IoMT help in designing and tuning to sophisticated custom software. Also, iTunes or Google Play catalogs have encompassed healthcare and wellness mobile apps. With synchronization with wearables like fitness trackers or pulsometers for using data collected via sensors placed on body for reporting/analysing health conditions, the Ovarian Reserve Test Market is there to take the healthcare vertical by storm in the next 10 years.

According to latest research by Persistence Market Research, ovarian reserve test market is set to witness steady growth during 2021-2031. Demand for ovarian reserve test market will witness steady recovery in short-term, with optimistic growth outlook in the long-run. Ethical issues and less number of skilled surgeons will mean limited opportunities in near future.

However, rising adoption of in-vitro fertilization techniques will provide momentum to the ovarian reserve test market. This age-related decline of follicles in the human ovary is supposed to be more than double when numbers fall below a critical figure of 25,000 at ~37.5 years of age. According to World Health Organization (WHO), the number of women age 60 and over will increase from about 336 million in 2000 to just over 1 billion in 2050.

Get Sample Copy of this Report@

Moreover, safety and efficacy associated with ovarian reserve tests is likely to increase the demand in the near future. Manufacturers are also developing home testing kits for ovarian reserve test also provides easy accessibility and availability for checkups which is likely to rise the demand.

Ovarian surgeries also play an important role in driving the market, since removal of cysts can also result in diminished ovarian follicle in women. Thus, all these factors are likely to increase the market growth in the forecast period.

According to the WHO, fertility issues affect one in ten couples, up to 80 million people globally, and this number is rising.The conventional AMH blood test can be used any day of the menstrual cycle However, the Elecsys AMH blood test provides more standardized results for assessing ovarian reserves.

Hence, the new test provides healthcare professionals to additional part on the routine clinical practice with more reliable results. This helps to provide streamline opportunity and focus on improving diagnostics in the area of women’s health. This is further to augment the demand for ovarian reserve test methods for women.

North America is set to witness the fastest growth over the forecast period of 2021-2031 owing to the healthcare system of the U.S. is well-known for its advanced structure and spending. The countries have the highest rate of diagnosis and treatment adoption among all the other countries resulting in a key region for the ovarian reserve test.Manufacturers are focusing on mergers and acquisitions to fulfill the demands of women overall health.

For instance, in May 19, 2021, Ro Acquires Modern Fertility to Accelerate Its Leadership in Women’s Health. Acquisition of high-growth reproductive health company transforms Ro’s women’s health vertical, laying the foundation for Ro to become the first choice for women’s healthcare needs

The Europe ovarian reserve test market is expected to grow at a profitable rate over the forecast period. This growth is owed to the presence of an increasing number of key players and the opportunistic approach to new investments in the field of ovarian reserve test.

Request for Table of Content@

Some of the leading manufacturers and suppliers of Ovarian Reserve Test include,

  • Beckman Coulter
  • Fujirebio
  • F. Hoffmann-La Roche Ltd
  • Everlywell
  • LabCorp
  • Modern Fertility
  • Future Family
  • LetsGetChecked
  • EggQ

Key Segments

By Test Type

  • Follicle Stimulating Hormone (FSH) Testing
  • Anti-Mullerian hormone (AMH) Testing
  • Antral Follicle Count Testing
  • Basal Follicle Stimulating Hormone Testing

By Sample Type

  • Blood
  • Vaginal Swab
  • Semen
  • Urine
  • Others

By Distribution Channel

  • Institutional Sales
    • Hospitals
    • IVF Centers
    • Diagnostic Centres
    • Ambulatory Surgical Centres
  • Retail Sales
    • Retail Pharmacies
    • Drug Stores
    • Online Pharmacies
    • Supermarket/Hypermarket

Access Full Report@

About us: Persistence Market Research

Contact us:

Persistence Market Research          
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales –

Matched content

Editor’s pick

Express Press Release Distribution